Pharmaceuticals, Biotechnology & Life Sciences

United Therapeutics (UTHR) is a biotech leader in vascular disease drugs, trading near a 52‑week high with solid P/E and P/B ratios—ideal for investors seeking growth and stability.

Teva secures EU approvals for two denosumab biosimilars, PONLIMSI and DEGEVMA, expanding its bone‑health portfolio and boosting market share prospects.

Patrys Limited: Melbourne biotech firm pioneers antibody‑based cancer therapies amid stock volatility, offering a glimpse of future oncology breakthroughs.

Fibrobiologics Inc. raises $1.5 M in a direct offering to fund fibroblast therapies for degenerative disc disease, MS, cancer and more, amid a brief stock dip and cautious market sentiment.

Abivax SA sees renewed investor confidence as Truist Securities issues a buy rating, backed by a strong pipeline of antiviral and therapeutic vaccines targeting high‑growth markets in Asia and Latin America.

Trulieve Cannabis Corp. delivers medical cannabis solutions for serious conditions, showcasing strong growth, market presence, and investor confidence.

Discover how Psyence Biomedical is pioneering psilocybin‑based longevity research, targeting aging biomarkers, and unlocking a multi‑billion‑dollar anti‑aging market.

Lexicon Pharmaceuticals: Biotech focus on diabetes, obesity, heart disease, mental health, cancer and eye disorders – navigating market volatility while driving breakthrough therapies.

Veru Inc. (Nasdaq: VRU) is a small‑cap biopharma focused on prostate cancer drugs, trading at $2.22 with a negative P/E and high volatility. Stay updated on clinical and regulatory news to assess its future upside.

Discover how Kura Oncology is pioneering personalized therapies for high‑unmet‑need cancers—from lung to pancreatic—while navigating biotech volatility and fueling future breakthroughs.